Skip to main content

Dialysis company shares plunge after Ozempic trial success vs. kidney trouble

The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.